May 13, 2026 04:19PM Omeros (OMER) Misses Q1 EPS by 12c

May 13, 2026 04:11PM Omeros (OMER) Misses Q1 EPS by 12c

Apr 16, 2026 08:50AM CMS assigns permanent J-code for Omeros' YARTEMLEA drug treatment

Mar 31, 2026 04:10PM Omeros (OMER) Tops Q4 EPS by 366c

Jan 27, 2026 09:02AM Omeros begins commercial sales of YARTEMLEA for rare blood disorder

Dec 29, 2025 05:11AM Omeros reschedules YARTEMLEA approval conference call to January 7

Dec 24, 2025 10:40AM Omeros stock soars after FDA approves first treatment for TA-TMA

Dec 24, 2025 10:11AM Omeros (OMER) halted on volatility, up 101%

Nov 18, 2025 11:50AM Increasing unusual put option volume: XLB OMER IVVD WIX HP JCI BOX

Nov 14, 2025 06:14AM Omeros (OMER) files mixed shelf

Nov 13, 2025 04:17PM Omeros (OMER) Tops Q3 EPS by 11c

Oct 16, 2025 08:33AM Omeros publishes study showing survival benefits of narsoplimab treatment

Oct 16, 2025 06:44AM Omeros Corp. (OMER) PT Raised to $20 at H.C. Wainwright

Oct 15, 2025 03:30PM Omeros (OMER) call put ratio 1 call to 1.2 puts on 41K contracts as share price up 147%

Oct 15, 2025 10:26AM Increasing unusual put option volume: CRML OMER FHN EXK FIVN

Sep 2, 2025 08:45AM Omeros publishes study on narsoplimab survival outcomes for TA-TMA patients

Aug 14, 2025 04:03PM Omeros (OMER) Tops Q2 EPS by 3c

Jun 30, 2025 06:52AM H.C. Wainwright Reiterates Buy Rating on Omeros Corp. (OMER)

Jun 27, 2025 08:31AM Omeros (OMER) Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA-TMA

May 15, 2025 04:09PM Omeros (OMER) Reports Q1 Loss of $0.58

May 12, 2025 08:41AM Omeros (OMER) Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026

May 6, 2025 09:16AM Omeros (OMER) FDA Accepts Resubmission of BLA for Narsoplimab for Hematopoietic Stem Cell TA-TMA and Assigns Late September PDUFA Date

Apr 10, 2025 09:10AM Omeros (OMER) Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros’ Proprietary OncotoX-AML Clinical Program

Mar 31, 2025 04:03PM Omeros (OMER) Tops Q4 EPS by 15c

Mar 21, 2025 09:15AM Omeros (OMER) Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program

Feb 20, 2025 09:11AM Omeros (OMER) Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA

Jan 16, 2025 09:16AM Omeros (OMER) Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint

Dec 23, 2024 10:19AM Increasing unusual option volume: INVZ QUBT RGTI OMER KULR HMC QBTS

Dec 23, 2024 07:07AM D. Boral Capital Starts Omeros Corp. (OMER) at Buy

Dec 19, 2024 09:15AM Omeros' (OMER) Narsoplimab Meets its Pivotal Trial Primary Endpoint

Dec 10, 2024 08:45AM Omeros (OMER) Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting

Nov 25, 2024 05:20AM Increasing unusual call option volume: PRGO MSTZ QBTS OMER RGTI XLI FRSH XLI FRSH ESTC HYLN

Nov 21, 2024 09:15AM Omeros (OMER) Provides Update on Progress Toward BLA Resubmission

Nov 14, 2024 06:37AM Rodman & Renshaw Starts Omeros Corp. (OMER) at Buy

Nov 13, 2024 04:04PM Omeros (OMER) Tops Q3 EPS by 13c

Aug 7, 2024 04:37PM Omeros (OMER) Misses Q2 EPS by 27c